Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Author:
Affiliation:
1. BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, California 94949, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01498
Reference45 articles.
1. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases
2. PARP inhibition: PARP1 and beyond
3. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
4. The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
5. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Cited by 141 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hybrid benzothiazole derived fused triazole/thiazole derivatives as versatile anti-Alzheimer agents: synthesis, characterization, biological evaluation and molecular docking studies;Journal of Molecular Structure;2024-12
2. The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancer;Medicinal Research Reviews;2024-08-24
3. New Cholinesterase inhibitors based on 1,2,4-triazole bearing benzenesulfonohydrazide skeleton: Synthesis, in vitro and in silico studies;Results in Chemistry;2024-08
4. AKT-dependent nuclear localization of EPRS1 activates PARP1 in breast cancer cells;Proceedings of the National Academy of Sciences;2024-07-16
5. PARP inhibitor boost the efficacy of photothermal therapy to TNBC through enhanced DNA damage and inhibited homologous recombination repair;Drug Delivery and Translational Research;2024-07-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3